Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE007 (JPN) (Dr. Dubois)
· consented 2022-07-01
Adverse events
5
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
severe
serious
assessed
2026-08-18
Grade 4 Decreased appetite — outcome: UNKNOWN; onset 2022-07-26 (study day 14); relationship: not assessed; serious criteria: life-threatening
severe
assessed
2026-08-18
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-07-26 (study day 14); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-07-31 (study day 19); relationship: N
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-31 (study day 19); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-08-02 (study day 21); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.